S2303: phase II/III trial of paclitaxel + ramucirumab ± nivolumab in gastric and esophageal adenocarcinoma (PARAMUNE)

By sjmartinez • May 2, 2025

Saeed A, Colby S, Oberstein PE, Duda DG, Park R, Agarwal R, Figueroa-Moseley C, Vaidya R, Unger JM, Guthrie KA, Rocha FG, Senthil M, Safyan RA, Wainberg ZA, Iqbal S, Chiorean EG, Philip PA. S2303: phase II/III trial of paclitaxel + ramucirumab ± nivolumab in gastric and esophageal adenocarcinoma (PARAMUNE). Future Oncol. 2025 May;21(11):1325-1331. doi: 10.1080/14796694.2025.2485020. Epub 2025 Mar 28. PMID: 40155326.

Tags: anti-programmed death-1, combined positive score, esophageal cancer, gastric, gastroesophageal junction, Hematology/Oncology, immunotherapy, paclitaxel, Publications, ramucirumab, vascular endothelial growth factor

Related Posts

ctDNA for MRD assessment is prognostic and predictive in newly diagnosed and relapsed/refractory lymphoma

Galanina N, Iqbal M, Tomassetti S, Nousome D, Tin A, Gillespie CP, Youngberg H, Miller P, Malhotra M, Widden H, Rodriguez A, Liu MC, Narkhede[...]

Biodistribution, shedding, and transmissibility of vusolimogene oderparepvec (RP1)

Wise-Draper TM, Robert C, Wong MK, Middleton MR, Sacco JJ, In GK, Muñoz Couselo E, Schadendorf D, Beasley GM, Niu J, Chmielowski B, Milhem MM,[...]

COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma

Ribas A, Robert C, Schadendorf D, Long GV, Tawbi H, Flaherty K, Ascierto PA, Nathan P, Rutkowski P, Leonov OV, Lorigan P, Prey S, Saponara[...]